USPTO serial 88258795
Serial No. 88258795
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SINGLETON, RUDY
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 88258795?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pain relief medication; Medicines for the treatment of gastrointestinal diseases; Anti-cancer preparations; Biological preparations for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Protein arrays for diagnosing allergies, and cancer; Therapeutic pharmaceutical for the treatment of gastrointestinal, cancer, infection, neurological, cardiovascular, musculoskeletal and immune system related diseases and disorders; Pharmaceutical preparations, namely, elixirs for the treatment of gastrointestinal, cancer, infection, neurological, cardiovascular, musculoskeletal and immune system related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of gastrointestinal, cancer, infection, neurological, cardiovascular, musculoskeletal and immune system related diseases and disorders; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Dietary and nutritional supplements; Medicinal preparations for the mouth to be applied in the form of drops, capsules, tablets and compressed tablets; Dietetic foods for treating celiac disease and gastrointestinal disorders; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment and prevention of gastrointestinal, cancer, infection, neurological, cardiovascular, musculoskeletal and immune system related diseases and disorders; Capsules made from starch sold empty for pharmaceuticals; Biometallic compounds being a component in pharmaceutical preparations for treatment and prevention of gastrointestinal, cancer, infection, neurological, cardiovascular, musculoskeletal and immune system related diseases and disorders; Biological preparations for the treatment and prevention of gastrointestinal, cancer, infection, neurological, cardiovascular, musculoskeletal and immune system related diseases and disorders; Transdermal patches for use in the treatment of musculoskeletal diseases; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Tumor suppressing agents; Nutraceuticals for the treatment of cardiovascular diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 22, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 22, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 26, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 22, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 22, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 22, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 19, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 17, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 17, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 17, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 16, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 21, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 21, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 1, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 12, 2019 | ALIE | ASSIGNED TO LIE | — |
| Mar 26, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 26, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 26, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 26, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 26, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 26, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Feb 2, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 15, 2019 | NWAP | NEW APPLICATION ENTERED | — |